Written Disclosure Therapy for Anxiety and Stress in Patients With Chronic Lung Disease

NCT ID: NCT00911794

Last Updated: 2009-06-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 66 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-01-31
• Study Completion Date: 2009-03-31

Brief Summary

The purpose of this study is to determine whether Written Disclosure Therapy (WDT) is of any benefit to patients with chronic lung diseases who are participating in pulmonary rehabilitation.

Detailed Description

Chronic lung diseases are typically associated with impaired quality of life, stress, and anxiety. Written disclosure therapy (WDT) reduces stress in patients with a variety of chronic illnesses. We sought to determine if written disclosure therapy benefits patients with chronic lung diseases when it is added as a component to the pulmonary rehabilitation program.

Conditions

Chronic Lung Diseases; COPD; Pulmonary Fibrosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Written Disclosure Therapy

Group Type: EXPERIMENTAL

Disclosure Writing (Written Disclosure Therapy)

Intervention Type: OTHER

Patients write about a stressful life experience

Controls

Group Type: SHAM_COMPARATOR

Neutral (Sham) Writing

Intervention Type: OTHER

Patients write about neutral subjects

Interventions

Disclosure Writing (Written Disclosure Therapy)

Patients write about a stressful life experience

Intervention Type: OTHER

Neutral (Sham) Writing

Patients write about neutral subjects

Intervention Type: OTHER

Other Intervention Names

Written Disclosure Therapy; Sham Writing (Controls that wrote about neutral subjects)

Eligibility Criteria

Inclusion Criteria

• Diagnosis of COPD or Pulmonary Fibrosis
• First time participants in Pulmonary Rehabilitation program

Exclusion Criteria

• Dementia
• Prior significant psychiatric illness
• Inability to complete the questionnaires
• Inability cooperate with spirometry
• Inability or to participate in outpatient follow-up over the six-month

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Stony Wold-Herbert Fund, Inc.

OTHER

Sponsor Role: collaborator

Winthrop University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Winthrop University Hospital

Principal Investigators

Adam Hurewitz, M.D.

Role: PRINCIPAL_INVESTIGATOR

Winthrop University Hospital

Other Identifiers

07300

Identifier Type: -

Identifier Source: org_study_id